Auven Therapeutics seeks to identify, acquire and/or partner and then invest in the development of novel therapeutic product candidates (both small-molecules and biologics) with a focus on mid-stage clinical development candidates.
We are an attractive partner for a biotech or early-stage developer of compounds, and in addition to providing an innovative and flexible deal structure, we offer the following:
- Rapid decision making on acquisition and partnering opportunities
- Ability to be creative with non-dilutive or minimally dilutive deal structures
- Retain share of value upon realization
- Capital and other resources allocated to move forward programs for resource-constrained companies
- Access to broad development expertise across multiple therapeutic areas
- Focused on accelerated development timelines
- Experience in driving products through global regulatory approval
- Dedicated, creative and focused, in-house intellectual property management to enhance value
- No risk of “shelving” your compound due to competition or strategic re-alignment
- Originator may retain significant input into future development
Auven Therapeutics invests according to the following criteria:
- Human proof-of-concept established
- Attractive commercial opportunity
- Compelling product profile that addresses a critical unmet medical need
- Strong intellectual property or other commercially relevant protection of the asset
- Executable clinical plan
- Conservative regulatory plan
- Well-defined pathway to a commercial manufacturing process